Market Intelligence, Clinical Progress, and High-Purity Reagents for Type 2 Diabetes and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DPP4/CD26 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DPP4 ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View DPP4 Products |
| Gene Delivery | DPP4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Native glycosylation pattern. |
View DPP4 Products |
| Benchmark Ab | Anti-DPP4 (Sequence of Begelomab) Recombinant positive control for binding assays. |
View DPP4 Products |
| Validator | DPP4 siRNA Set For knockdown verification and specificity controls. |
View DPP4 Products |
| Related Target: DPP8 | DPP8 Homolog Protein Selectivity counter-screening (avoid off-target toxicity). |
View DPP8 Products |
| Related Target: FAP | Fibroblast Activation Protein (FAP) Family member for subfamily specificity profiling. |
View FAP Products |
| Related Target: GLP-1R | GLP-1 Receptor Downstream pathway partner for combination therapy studies. |
View GLP-1R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog DPP4 proteins available with >95% purity; sequence verified by Mass Spec |
| DPP8/DPP9 Selectivity (Avoid toxicity) | Homolog panel proteins (DPP8, DPP9, FAP) strictly verified for counter-screening |
| Enzymatic vs Non-enzymatic inhibition | Active site mutant (E205A/S630A) and Wild-Type proteins for mechanistic delineation |
| False Positives in Binding Assays | Validated siRNA and Clinical Benchmark Antibodies included for target specificity verification |
Live DPP4/CD26 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The DPP4 inhibitor market (Gliptins) has matured with established small molecules like Sitagliptin and Saxagliptin dominating Type 2 Diabetes treatment. However, the race is intensifying toward next-generation biologics targeting CD26 in immuno-oncology and long-acting combination therapies. As first-generation therapies face generic competition, the next wave of R&D targets selective enzymatic inhibition with minimized DPP8/DPP9 cross-reactivity, and novel antibody-based modalities for solid tumors and graft-versus-host disease (GvHD), leveraging CD26's co-stimulatory role and internalization properties. The competitive landscape is shifting from traditional diabetes players (Merck, Novartis) to emerging biotechs (Biotest, Y's Therapeutics) focusing on oncology indications where CD26 acts as a T-cell activation marker.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (Gliptins) | Merck, Novartis, AstraZeneca | Type 2 Diabetes | Selectivity Assay (Need DPP8/DPP9 homolog proteins to avoid toxicity) |
| Monoclonal Antibodies (Anti-CD26) | Biotest, Y's Therapeutics, Emerging Biotechs | GvHD, Solid Tumors, T-Cell Lymphoma | Internalization Assay & Epitope Mapping (Need high-purity ECD-Fc for ADC development) |
| Fusion Proteins | Biosimilar Developers | Inflammatory Diseases | Binding Affinity (Need high-avidity Fc fusion format) |
| Bi-specifics | Various Biotech (Early Stage) | Immunotherapy | Heterodimer Validation (Need Cross-reactive Abs) |